Varian presented publicly, at the American Association for Cancer Research (AACR) Annual Meeting in Atlanta, the first pre-clinical results of its research on ultra-high dose rate cancer treatments with protons. Known as Flash therapy, it is a non-invasive therapy for cancer delivering high doses of radiation in ultra-high-speeds and according to the company, represents the potential for a major breakthrough in the treatment of cancer. The preclinical Flash therapy results presented at AACR showed reduced toxicity in healthy tissues and organs. Conducted on a clinical device capable of translation to humans, the Flash therapy preclinical tests, compared to conventional proton treatments, displayed 25%-30% less damage to lung tissue, resulting in less fibrosis of the lung, and an average of 35% reduction in skin dermatitis during treatment.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.